《中国糖尿病杂志》官方网站

20

您的位置:首页 > 中国糖尿病杂志 > 2014年 > 7期

一天一次Det控制FPG的疗效和安全性评价

来自:中国糖尿病杂志  编辑:邹大进 |点击数:|2014-07-31

 药物研究动态

  [摘要] FPG对糖尿病患者整体血糖水平和心脑血管糖尿病并发症的防治都至关重要。Det(Det)是一种长效基础胰岛素,降糖作用持久且平稳。一天一次Det能有效控制FPG,还能降低治疗中的个体变异性。与中效人胰岛素和长效甘精胰岛素相比,Det治疗的患者有较低的低血糖发生率和较少的体重增加。鉴于其优良的疗效和安全性,一天一次Det治疗不受体重和年龄的限制,适应证广泛,是控制FPG的理想选择。

  [Abstract] Fasting plasma glucose (FPG) is of great importance in diabetes care. FPG not only ties up tightly with postprandial glucose and hence the overall blood glucose, but also plays a key role in the prevention of cardiovascular diseases in diabetic patients. Basal insulin is an effective way in improving FPG. Insulin detemir is an acylated insulin analog achieving extended action through self-association and reversible albumin binding, which, together with its solubility underpin a greater within-patient consistency in glucose-lowering time–action profile compared with other basal insulins. Due to its unique pharmacokinetic and pharmacodynamics characteristics, once daily insulin detemir demonstrated a stable and long-lasting glucose lowering effect. A large body of evidence from randomized controlled clinical trials and from observational studies showed that once daily insulin detemir effectively decreased PFG levels and meanwhile reduced the within-subject variability in FPG. Compared with insulin NPH and insulin glargine, patients on once daily insulin detemir exhibited a significantly lowered incidence of hypoglycemia and reduced weight gain. As a consequence of such great efficacy and excellent safety profile, insulin detemir is not limited by body weight or age of the patient. Therefore, insulin detemir can be used to control FPG in patients with type 1 diabetes or type 2 diabetes whether they are obese or adolescent or pregnancy. Taken together, once daily insulin detemir is an optimal choice to control FPG in real clinical practice.

  【关键词】糖尿病;FPG;Det;一天一次

  [Key words] Diabetes mellitus;Fasting plasma glucose (FPG);Detemir ;Once a day

上一篇:胰升血糖素与肝源性胰岛素抵抗研究进展 下一篇:已经是最后一篇了